Therapy Detail

Therapy Name Tamoxifen
Therapy Description

Nolvadex (tamoxifen) is a selective estrogen receptor modulator (SERM), which decreases DNA synthesis and cell growth (NCI Drug Dictionary). Nolvadex (tamoxifen) is FDA approved for breast cancer (


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Tamoxifen Nolvadex ICI-46474 Hormone Antineoplastics 5 Nolvadex (tamoxifen) is a selective estrogen receptor modulator (SERM), which decreases DNA synthesis and cell growth (NCI Drug Dictionary). Nolvadex (tamoxifen) is FDA approved for breast cancer (
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT02278120 Phase III Tamoxifen Letrozole Ribociclib Goserelin Anastrozole Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (MONALEESA-7) Active, not recruiting
NCT02228681 Phase II Tamoxifen Medroxyprogesterone Everolimus + Letrozole Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer Active, not recruiting
NCT02269670 Phase II Tamoxifen Everolimus Megestrol acetate Letrozole Fulvestrant Anastrozole Phase II Study of Everolimus Beyond Progression Active, not recruiting
NCT02040857 Phase II Exemestane Palbociclib Tamoxifen Letrozole Anastrozole Palbociclib + Endocrine Therapy for HR + BrCa Active, not recruiting
NCT03219476 Phase II Anastrozole Letrozole Tamoxifen Exemestane Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive HERNegative Node-Negative Breast Cancer Patients to Assess Responses and Mechanisms of Endocrine Resistance Recruiting
NCT02366130 Phase II Tamoxifen Denosumab + Radium Ra 223 dichloride Fulvestrant Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer Active, not recruiting
NCT03238703 FDA approved Tamoxifen Exemestane Toremifene Anastrozole Letrozole Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer Withdrawn
NCT00900744 FDA approved Tamoxifen A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6 Completed
NCT02753686 Phase I Tamoxifen Exemestane Fulvestrant Letrozole Anastrozole Everolimus + Exemestane Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight) Recruiting
NCT02764541 Phase II Palbociclib Palbociclib + Tamoxifen Letrozole Tamoxifen Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS) Recruiting
NCT02311933 Phase II Z-endoxifen HCl Tamoxifen Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer Active, not recruiting
NCT01674140 Phase III Goserelin Anastrozole Letrozole Leuprolide Everolimus Tamoxifen Exemestane S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Recruiting
NCT02913430 Phase II Tamoxifen Fulvestrant Phase II Treatment of Metastatic Breast Cancer With Fulvestrant or Tamoxifen Recruiting
NCT01124695 Phase II Tamoxifen Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Unknown status
NCT02993159 Phase II Afimoxifene Tamoxifen Tamoxifen Citrate or Afimoxifene in Treating Patients With Estrogen Receptor Positive Breast Cancer Recruiting
NCT01272037 Phase III Anastrozole Letrozole Tamoxifen Exemestane Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Active, not recruiting
NCT01293032 Phase I Tamoxifen Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer Completed
NCT00492687 Phase II Carboplatin Temozolomide Tamoxifen Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas Unknown status
NCT02476786 Phase II Anastrozole Fulvestrant Goserelin Tamoxifen Exemestane Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score Recruiting
NCT02197897 Phase II Tamoxifen Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors Recruiting
NCT02206984 Phase I Tamoxifen Anastrozole Fulvestrant Endocrine Response in Women With Invasive Lobular Breast Cancer Recruiting
NCT02936206 Phase I Tamoxifen Fulvestrant Examination of Breast Cancer Cells of Pre-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant. Recruiting
NCT02630693 Phase II Palbociclib Fulvestrant Tamoxifen Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer Active, not recruiting
NCT02788201 Phase II Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma Recruiting
NCT01027416 Phase I Tamoxifen Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients Completed